![Isabelle Riviere](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Isabelle Riviere
Directeur/Membre du Conseil chez Centre For Commercialization of Cancer Immunotherapy
Profil
Isabelle Riviere is the founder of Juno Therapeutics, Inc. which was founded in 2013.
Currently, she holds the position of Director at the Centre For Commercialization of Cancer Immunotherapy.
Postes actifs de Isabelle Riviere
Sociétés | Poste | Début |
---|---|---|
Centre For Commercialization of Cancer Immunotherapy
![]() Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada. | Directeur/Membre du Conseil | - |
Anciens postes connus de Isabelle Riviere
Sociétés | Poste | Fin |
---|---|---|
JUNO THERAPEUTICS INC | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Juno Therapeutics, Inc.
![]() Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
Centre For Commercialization of Cancer Immunotherapy
![]() Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada. |